Skip to content
DataLookout
Menu

NCT05763277

Ate-Bev Early Response Prediction Model in Advanced HCC

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 31, 2025 to Dec 31, 2027
    • Eligibility criteria expanded, about 4 words
    • Study completion pushed from Dec 31, 2026 to Dec 31, 2028
  2. Notable Primary completion date: May 22, 2024 to Dec 31, 2025
    • Study completion date: May 22, 2025 to Dec 31, 2026
    v3
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

progression free survival
Timeframe: the follow up will be continued until June 22th 2025.

Secondary (1)

Overall survival

Arms and interventions

Ate-Bev

Individuals diagnosed with advanced hepatocellular carcinoma and treated with atezolizumab-bevacizumab between the ages of 18-80 were included. According to the recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, patients with comorbidities were excluded.

Diagnostic tests: Early response evaluation

Sites

1 site in 1 country

  • Seoul National University HospitalSeoul, South Korea